Physician profile
Jian Chen
NPI 1679568612
$2,601.14
in general payments reported to CMS, 2019-2025
25 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $123 · 2021: $166 · 2022: $506 · 2023: $202 · 2024: $579 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $434.61 | 2022-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $391.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Enterra Medical, INC. | $184.43 | 2025 | |
| Abbvie INC. | $183.33 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $161.50 | 2019-2023 | Arexvy, Shingrix |
| Silk Road Medical, INC. | $150.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.73 | 2022-2025 | |
| Abbott Laboratories | $130.04 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Mannkind Corporation | $113.07 | 2024 | |
| Lilly USA, LLC | $102.12 | 2022-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $96.30 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.07 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Supernus Pharmaceuticals, INC. | $51.74 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $42.61 | 2019-2023 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.73 | 2019-2022 | |
| Pfizer INC. | $31.07 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $23.34 | 2023 | Edarbyclor |
| Merck Sharp & Dohme LLC | $23.24 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $17.32 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $16.71 | 2024 | Farxiga |
| Upsher-Smith Laboratories LLC | $15.81 | 2020 | |
| Exact Sciences Corporation | $14.84 | 2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $13.36 | 2024 | Aplenzin |
| Collegium Pharmaceutical, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jian Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.